Brickell Biotech enters into licensing deal with Merz for new retinoid therapy
The deal grants Merz an exclusive North American license, with certain additional international rights, for the development and commercialization of BBI-3000, to treat skin conditions known to be
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.